Parikh SV, et al.. Update on lupus nephritis: Core curriculum 2020. Am J Kidney Dis 2020; 76:265−281. doi: 10.1053/j.ajkd.2019.10.017

• PubMed
Parikh SV, . Update on lupus nephritis: Core curriculum 2020. Am J Kidney Dis 2020; 76:265−281. doi: 10.1053/j.ajkd.2019.10.017)| false
• Search Google Scholar
• Export Citation

Furie R, et al.. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383:1117−1128. doi: 0.1056/NEJMoa2001180

• PubMed
Furie R, . Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383:1117−1128. doi: 0.1056/NEJMoa2001180)| false
• Search Google Scholar
• Export Citation

Atisha-Fregoso Y, et al.. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol [published online ahead of print August 4, 2020]. doi: 10.1002/art.41466; https://onlinelibrary.wiley.com/doi/10.1002/art.41466

• PubMed
Atisha-Fregoso Y, . Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol [published online ahead of print August 4, 2020]. doi: 10.1002/art.41466; https://onlinelibrary.wiley.com/doi/10.1002/art.41466)| false
• Search Google Scholar
• Export Citation

Furie R, et al.. A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis (abstract). Arthritis Rheumatol 2019; 71 (Suppl 10):939. https://acrabstracts.org/abstract/a-phase-ii-randomized-double-blind-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-obinutuzumab-or-placebo-in-combination-with-mycophenolate-mofetil-in-patients-with-active-class-iii/

• PubMed
Furie R, . A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis (abstract). Arthritis Rheumatol 2019; 71 (Suppl 10):939. https://acrabstracts.org/abstract/a-phase-ii-randomized-double-blind-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-obinutuzumab-or-placebo-in-combination-with-mycophenolate-mofetil-in-patients-with-active-class-iii/)| false
• Search Google Scholar
• Export Citation

Rovin BH, et al.. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 2019; 95:219−231. doi: 10.1016/j.kint.2018.08.025

• PubMed
Rovin BH, . A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 2019; 95:219−231. doi: 10.1016/j.kint.2018.08.025)| false
• Search Google Scholar
• Export Citation

Arriens C, et al.. AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis. Aurinia. June 5, 2020. https://d1io3yog0oux5.cloudfront.net/_b9287cb2b9b32ac3fbb5d08113841567/auriniapharma/db/246/1327/pdf/EULAR+2020+AURORA_Presentation+Deck+05Jun2020.pdf

• PubMed
Arriens C, . AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis. Aurinia. June 5, 2020. https://d1io3yog0oux5.cloudfront.net/_b9287cb2b9b32ac3fbb5d08113841567/auriniapharma/db/246/1327/pdf/EULAR+2020+AURORA_Presentation+Deck+05Jun2020.pdf)| false
• Search Google Scholar
• Export Citation

Aurinia. FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis. January 22, 2021. https://ir.auriniapharma.com/press-releases/detail/210

• PubMed
Aurinia. FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis. January 22, 2021. https://ir.auriniapharma.com/press-releases/detail/210)| false
• Search Google Scholar
• Export Citation

MetroHealth Medical Center. Pentoxifylline in Lupus Nephritis (Pentoxifylline). ClinicalTrials.gov: NCT03859570. https://clinicaltrials.gov/ct2/show/NCT03859570

• PubMed
MetroHealth Medical Center. Pentoxifylline in Lupus Nephritis (Pentoxifylline). ClinicalTrials.gov: NCT03859570. https://clinicaltrials.gov/ct2/show/NCT03859570)| false
• Search Google Scholar
• Export Citation

BeiGene. Zanubrutinib in Participants with Active Proliferative Lupus Nephritis. ClinicalTrials.gov: NCT04643470. https://clinicaltrials.gov/ct2/show/NCT04643470

• PubMed
BeiGene. Zanubrutinib in Participants with Active Proliferative Lupus Nephritis. ClinicalTrials.gov: NCT04643470. https://clinicaltrials.gov/ct2/show/NCT04643470)| false
• Search Google Scholar
• Export Citation

Janssen Research & Development, LLC. A Study of Guselkumab in Participants with Active Lupus Nephritis (ORCHID-LN). ClinicalTrials.gov: NCT04376827. https://clinicaltrials.gov/ct2/show/NCT04376827

• PubMed
Janssen Research & Development, LLC. A Study of Guselkumab in Participants with Active Lupus Nephritis (ORCHID-LN). ClinicalTrials.gov: NCT04376827. https://clinicaltrials.gov/ct2/show/NCT04376827)| false
• Search Google Scholar
• Export Citation